StayCurrentMD · Pheochromocytoma and Paraganglioma PDQ®
Follow
Guideline1 min read·Published Mar 2020Older

Pheochromocytoma and Paraganglioma PDQ®

Guideline · Mar 2020 · 1 min read

In brief

In brief

Comprehensive clinical reference from NCI covering diagnosis, staging, and treatment approaches for childhood pheochromocytoma and paraganglioma. Provides evidence-based guidance for managing these rare catecholamine-secreting neuroendocrine tumors in pediatric patients.

  • Pheochromocytomas arise from adrenal medulla; paragangliomas from extra-adrenal chromaffin tissue—both secrete catecholamines.
  • Pediatric cases often present with sustained hypertension, headache, sweating, and palpitations due to excess catecholamine release.
  • Genetic syndromes (MEN2, VHL, NF1, SDH mutations) account for majority of pediatric cases—family history and genetic testing crucial.
  • Preoperative alpha-blockade essential to prevent hypertensive crisis during surgical resection, the primary curative treatment.
  • Malignant potential exists; long-term surveillance required for metastatic disease and recurrence, especially in syndromic cases.

Written by the GCMD Library team from the guideline.

National Institute of Health and National Cancer Institute Childhood Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version

Read it at the source ↗

This guideline lives on cancer.gov.

Open it on cancer.gov ↗
Try
Intelligent Search· scoped to this guideline · not medical adviceSearch the whole library →